BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Osel, Inc. Names Levy President, Announces New Board Members, And Start Of Phase I Trial


10/19/2005 5:08:57 PM

SANTA CLARA, Calif., July 19 /PRNewswire/ -- Osel, Inc., the Bacterio- Therapeutics company, today announced that Ralph Levy has joined Osel as President. Mr. Levy, a veteran of more than 30 years in biotechnology / pharmaceutical companies, has also announced the appointment of Winnie Wan to the Board of Directors, formation of a new Clinical Advisory Board, and that their first product candidate, LACTIN-V entered Phase I clinical trials in June.

Mr. Levy helped to build SangStat Medical Corporation from 4 employees to a public company with over 300 employees, selling last year for $620 million to Genzyme Corporation. Referring to Mr. Levy's extensive experience in clinical development, regulatory issues, manufacturing, facilities, and operations, Peter Lee, M.D., founder and Chairman of Osel Inc., said, "We are pleased and excited that Ralph has joined Osel; his experience, insight and dedication are the skills we need to take Osel to the next level."

In discussing recent developments, Mr. Levy said, "This month has been an exciting and seminal month for Osel: we began our Phase I clinical trial of LACTIN-V as a treatment for bacterial vaginosis, submitted a second IND for a recurring urinary tract infection indication, and filled in needed expertise on our various Boards. Osel is honored to have Dr. Wan and the vast industry experience she brings on our Board of Directors." Winnie H. Wan, Ph.D., chief executive officer of Aria Biosystems, who was previously President and CEO of GeneTrol Biotherapeutics.

In addition, Osel has appointed new Clinical Advisory Board members: Walter Stamm, MD, Professor, Medicine/Infectious Diseases, at the University of Washington, Seattle, WA, who graduated cum laude from Harvard Medical School, has over 30 years experience and will advise the company on recurrent urinary tract infection.

Sharon Hillier, Ph.D., Department of Obstetrics, Gynecology and Reproductive Sciences, Magee-Women's Hospital, Pittsburgh, PA, has a Ph.D. from Washington State University and brings 20 years experience to the subject of bacterial vaginitis. Both clinical researchers are highly honored and world recognized experts in their field.

About Osel

Osel, Inc. is the leading company in the emerging field of Bacterio-Therapeutics. The company's business is commercializing therapeutic products, through the exploitation of recent scientific discoveries demonstrating the central role of naturally occurring mucosal bacteria in the maintenance of health and the prevention of disease. Osel's mission is to harness the protective properties of these specialized non-pathogenic bacteria as a basis for a series of innovative products initially targeted for the prevention and treatment of diseases of the genitourinary and gastrointestinal tracts.

Osel, Inc.

CONTACT: Ralph Levy, President of Osel Inc., +1-408-986-0012, ext. 206,or cell, +1-415-699-0135, or rlevy@oselinc.com



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES